CCR2 and its ligands are implicated in numerous inflammatory and neurodegenerative diseases 2 including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, and diabetic nephropathy, as well as cancer 3 . These disease associations have motivated numerous preclinical studies and clinical trials 4 (see http://www.clinicaltrials. gov) in search of therapies that target the CCR2-chemokine axis. To aid drug discovery efforts 5 , here we solve a structure of CCR2 in a ternary complex with an orthosteric (BMS-681 (ref. 6) ) and allosteric (CCR2-RA-[R] 7 ) antagonist. BMS-681 inhibits chemokine binding by occupying the orthosteric pocket of the receptor in a previously unseen binding mode.
overlaps with the G-protein-binding site in homologous receptors (Fig. 1f ). As for other chemokine receptors [9] [10] [11] [12] , CCR2 is expected to have two conserved disulfide bonds in its extracellular domains, with Cys32-Cys277 connecting the amino (N) terminus to ECL3 (NT-ECL3), and Cys113-Cys190 connecting TM3 to ECL2. Electron density is apparent for the ECL2-TM3 disulfide bond but not for the N-terminal residues 1-36 or the NT-ECL3 disulfide bond (Fig. 1b, c) . Because the NT-ECL3 disulfide bond has been shown to be important for CCR2 signalling 13 , its absence is unlikely to be an inherent feature of the receptor; instead, it might be caused by strain of the bond in the ligand-bound state of the receptor 14 , possibly exacerbated by solvent exposure and radiation damage of the crystals 15 .
As with other chemokine receptors, the extracellular orthosteric pocket of CCR2 can be divided into a major and a minor subpocket, defined by helices III-VII, and helices I-III and VII, respectively, and separated by residues Y120 3.32 and E291 7.39 (superscript indicates residue number according to Ballesteros-Weinstein nomenclature). BMS-681 binds predominantly in the minor subpocket ( Fig. 2a, b ) and buries 366.3 Å 2 of surface area. The 6-trifluoromethyl quinazoline moiety protrudes between helices I and VII towards the lipid bilayer, while the tri-substituted cyclohexane packs against W98 2.60 . The γ -lactam secondary exocyclic amine forms a hydrogen bond with the hydroxyl of T292 7.40 , which is critical for binding of chemically related compounds such as BMS-558 (compound 22 in ref. 16 ) and the Teijin lead series 17, 18 . This amine is also within hydrogen-bonding distance from the backbone carbonyl of Q288 7.36 . The carbonyl oxygen of the γ -lactam forms a hydrogen bond with Y49 1.39 , which itself is hydrogen-bonded to the side chain of T292 7.40 . The N1 nitrogen of the quinazoline is within 4 Å of the Q288 7.36 side chain. The protonated tertiary amine on the cyclohexane ring is proximal to a structured water molecule in the binding site. Some CCR2 antagonists, particularly those containing a basic amine, are known to depend on the conserved E291 7.39 in the receptor 19 ; however, no direct interaction is observed between E291 7. 39 and BMS-681. The receptor-bound, bioactive conformation of BMS-681 is strikingly similar to the crystallographic conformation of free BMS-681 ( Fig. 2c and Extended Data Table 2 ), suggesting the absence of internal strain in the bound state.
BMS-681 engages several residues that are critical for CCL2 binding and/or activation of CCR2 (refs 17, 18) including Y49 1.39 , W98 2.60 , Y120 3.32 , and T292 7.40 . Thus, it seems to directly compete with chemokine binding to the orthosteric pocket. Additionally, by inserting between helices I and VII, BMS-681 may put strain onto residues C32-V37 connecting TM1 to ECL3, destabilize the conserved NT-ECL3 disulfide bond (absent in the structure), and prevent the N terminus and TM1 from adopting a productive chemokine binding conformation observed in homologous receptor-chemokine structures 11, 12 (Extended Data Fig. 2 ).
On the opposite side of the receptor, CCR2-RA-[R] is caged by the intracellular ends of helices I-III and VI-VIII and buries 297.8 Å 2 of surface area. The inner hydrophobic part of the cage is made by V63 1.53 , L67 1.57 , L81 2.43 , L134 3.46 , A241 6.33 , V244 6.36 , I245 6.37 , Y305 7.53 , and F312 8.50 , while the outer (cytosol-facing) polar part consists of T77 2.39 , R138 3.50 , G309 8.47 , K311 8.49 , and Y315 8.53 (Fig. 2d, e ), as well as the backbones of engineered R237 6.29 and K240 6.32 . The binding pocket of CCR2-RA-[R] is highly enclosed and possesses a balanced combination of hydrophobic and polar features, all of which favours pocket 'druggability' 5 . Owing to the lack of a side-chain on G309 8.47 , the hydroxyl and pyrrolone carbonyl groups of CCR2-RA-[R] can hydrogen-bond to the exposed backbone amides of E310 8.48 , K311 8.49 , and F312 8.50 (Fig. 2d, e ). The acetyl group of the compound resides near the terminal amine of K311 8.49 . The critical roles of V244 6.36 , Y305 7.53 , K311 8.49 , and F312 8.50 in CCR2-RA-[R] binding were established by an earlier mutagenesis study 20 . Because homologues of several residues in the CCR2-RA-[R] binding pocket directly couple to the G protein in bovine rhodopsin 21 and the β 2 adrenergic receptor (β 2 AR) 22 structures (Extended Data Fig. 3 ), CCR2-RA-[R] appears to sterically interfere with G-protein binding to CCR2.
The structure suggests an interesting symmetrical mechanism for the concurrent antagonistic action of the two compounds. BMS-681 interferes with chemokine binding directly and with G-protein coupling indirectly, by stabilizing an inactive, presumably G-proteinincompatible 6 , conformation of the receptor. Conversely, CCR2-RA-[R] directly prevents G-protein coupling and allosterically inhibits binding of the CCL2 chemokine 23 , which, like most GPCR agonists, requires an active, G-protein-associated receptor for high affinity binding 23 . Bi-directional allosteric communication between the extra-and intracellular sides of the receptor is reminiscent of that previously observed in adenosine A 2A receptor (AA 2A R) 24 and β 2 AR 25 using allosteric inverse agonist antibodies/nanobodies that target the same epitope as CCR2-RA-[R]. Similar to these antibodies, CCR2-RA-[R] was previously shown to allosterically enhance, and to be allosterically enhanced by, binding of orthosteric antagonists 23 , demonstrating positive binding cooperativity.
We further characterized this cooperativity by studying the binding of BMS-681 to wild-type CCR2 and the crystallization construct CCR2-T4L using previously characterized radioactive probes [ 3 H]INCB-3344 ECL3   VII   VI   V   IV   ECL2   III  ECL1   II   I   ICL3   V  VI   ICL2   VII  VIII   I   ICL1   III   II   IV   Temperature (°C)   30 Table 3 ).
In kinetic radioligand experiments, the presence of BMS-681 also increased total binding of [ 3 H]CCR2-RA to both wild-type CCR2 and CCR2-T4L, with the increase as high as 62% in the case of CCR2-T4L (Extended Data Fig. 4c, d and Extended Data Table 4 ). BMS-681 (1 μ M) decreased the dissociation rate constant of [ 3 H]CCR2-RA, while producing a slight increase (wild-type CCR2) or no change (CCR2-T4L) in the observed association rate constants. Moreover, for CCR2-T4L, the presence of BMS-681 changed the biphasic dissociation profile of [ 3 H] CCR2-RA to monophasic, suggesting stabilization of the receptor population in a homogenous conformational state (Extended Data Table 4 ). Along with the stability and equilibrium binding data, these results further corroborate the hypothesis that BMS-681 and CCR2-RA-[R] cooperatively stabilize a preferred inactive conformation of CCR2-T4L.
We next analysed the structure of double-antagonist-bound CCR2-T4L to better understand this conformation. The plethora of existing class A GPCR structures suggests a conserved conformational signature of an active receptor state 26 . This signature involves increased separation between the intracellular end of helix VI and the rest of the TM bundle, an inward repositioning and rotation of helix VII, and concerted repacking of the highly conserved microswitches R 3.50 (of the DR 3.50 Y motif), Y 5.58 , and Y 7.53 (of the NPxxY 7.53 motif) ( Fig. 3a, b ) to form an intracellular binding interface for G protein. Furthermore, rather than adopting either an 'on' or 'off ' state, receptors can occupy an ensemble of intermediate conformations 27 . The active state signature is fully represented in US28, the only agonist-bound chemokine receptor crystallized so far 12 (Fig. 3a-c) . By contrast, the double-antagonistbound CCR2 structure appears to occupy the opposite end of the activation spectrum as it shares the conformational microswitch signatures of the most inactive GPCR structures observed thus far ( Fig. 3a-e ).
As in the inactive CCR5-maraviroc complex 10 , the intracellular ends of CCR2 helices III and VI are close together, and the conserved R 3.50 interacts with D 3.49 and T 2.39 , effectively disrupting the G-proteinbinding pocket ( Fig. 3b, d, e ). Similarly, in both CCR2 and CCR5 structures, the intracellular end of helix VII is in the inactive outwardfacing conformation with Y 7.53 pointing towards helix II rather than the centre of the bundle. However, in CCR5, Y 5.58 is oriented towards the centre of the bundle, whereas in the present CCR2 structure, it faces the lipid and is sterically blocked from approaching R 3.50 and Y 7.53 by F 6.38 (Fig. 3d, e ). The net result of these interactions is that the crystallographically observed conformation of CCR2 appears to be even more inactive than that of CCR5 and most similar to dark rhodopsin 28 and Fab-bound β 2 AR 29 . Although receptor construct engineering appears to contribute to stabilization of this inactive state, the ligand binding and thermal denaturation data suggest that the concerted action of the two antagonists is also important. By directly interacting with the conserved activation microswitch residues, CCR2-RA-[R] is perfectly positioned to stabilize this inactive state: it sterically blocks Y 7.53 from populating the active conformation and is propped against R 3.50 , restricting its orientation away from the G-protein interface (Fig. 3b ). Although located 30 Å away, BMS-681 appears to cooperate with CCR2-RA-[R] through their common interactions with helix VII, which moves outwards on the intracellular side (opposite to its movement during activation) and inwards on the extracellular side (relative to CCR5 and US28) ( Fig. 3f ).
(structurally more inactive) ECL2   VIII   VI   VII   V   II   I   VIII   VI   VII   V   II   I   BMS-681   VIII   III   VII   II   I   VIII   III   VII   II   I III   II   IV   I   VIII   VII  VI  V   III   II   IV   I   VIII   CCR2- The CCR2 structure has general implications for the design of drugs targeting chemokine receptors as a family. As with most proteinprotein interfaces, the orthosteric binding pockets of chemokine receptors are large, wide open, and highly polar. Chemokines explore numerous hotspots within these pockets and their binding is additionally reinforced by the interaction with the flexible N termini of the receptors 11, 12 (Fig. 4a ), collectively making for an extensive and versatile interaction that is conceptually difficult to inhibit with small molecules. The structure of CCR2 with BMS-681 and CCR2-RA-[R] extends the repertoire of ideas that can be used to overcome these obstacles. The binding mode of BMS-681 ( Fig. 4b) contrasts with both the binding mode of maraviroc to CCR5 (Fig. 4c) where the ligand spans the major and the minor subpockets of the receptor, and that of IT1t to CXCR4 (Fig. 4d) where the ligand is entirely accommodated in the minor subpocket. While occupying the minor subpocket of CCR2, BMS-681 protrudes between helices I and VII towards the lipid bilayer (Fig. 4b) in an interaction facilitated by the trifluoromethyl group that is often present in CCR2 antagonists 30 . This interaction enables hydrophobic anchoring of BMS-681 to the otherwise polar and open binding site of CCR2; by doing so, it parallels the role of other unique non-polar subpockets exploited by crystallized small molecule antagonists of CCR5 and CXCR4 ( Fig. 4b-d ). The novel subpocket explored by BMS-681 may have an additional advantage of disrupting the chemokine-compatible conformation of the receptor N terminus (Extended Data Fig. 2) .
CCR2-RA-[R] demonstrates a previously unseen binding mode within an allosteric pocket on the intracellular side of CCR2. Although relatively small, this pocket has a desirable balance of polarity and hydrophobicity (Figs 2e, 4e) . Homologous pockets may be present in other chemokine receptors, owing to a conserved G 8.47 ; in fact, compound binding in homologous regions has been indirectly demonstrated for CCR1 and CCR5, and directly for CCR4 (ref. 31 ), CXCR1, and CXCR2 (ref. 32) . In most other receptors that have been crystallized thus far, the non-glycine residue at position 8.47 appears to both reduce the pocket volume and block access to the backbone amides of helix 8; consequently, the homologous pockets in these receptors may not be druggable although negative allosteric modulation with antibodies and nanobodies targeting the same region has been reported 24, 25 . By simultaneously competing with G protein and blocking activationrelated conformational changes, compound binding in the allosteric pocket seems a powerful way to antagonize the receptor. Therefore, for receptors in which the allosteric pocket is druggable, targeting it with small molecules may open new avenues for GPCR drug discovery.
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Design and expression of CCR2-T4L fusion constructs. The sequence of human CCR2 isoform B (Uniprot ID P41597-2) was engineered for crystallization by truncation of C-terminal residues 329-360 and by grafting T4 lysozyme (T4L) into the ICL3. In the process of construct optimization, the native CCR2 residues between L226 5.62 and R240 6.32 (L226 5.62 -KTLLRCRNEKKRH-R240 6.32 ) were removed and replaced with corresponding residues from the crystallized structure of M2 muscarinic acetylcholine receptor (PDB accession number 3UON, resulting amino-acid sequence S226 5.62 -RASKSRI-T4L-PPPSREK-K240 6.32 ). The presence of T4L in ICL3 is expected to prevent receptor activation; however the similar affinities of BMS-681 and CCR2-RA-[R] for both wild-type (WT) CCR2 and CCR2-T4L (Extended Data Fig. 4a, b and Extended Data Table 3 ) suggest that the fusion construct is a good surrogate of WT CCR2 for understanding ligand recognition.
The CCR2-T4L coding sequence was cloned into a modified pFastBac1 vector (Invitrogen) with an HA signal sequence followed by a Flag tag at the N terminus and a PreScission protease site followed by a 10× His tag and another Flag tag at the C terminus. The receptor was expressed in Spodoptera frugiperda (Sf9) cells. High-titre recombinant baculovirus (> 10 9 viral particles per millilitre) was obtained using the Bac-to-Bac Baculovirus Expression System (Invitrogen) as previously described 11 . Sf9 cells at a cell density of (2-3) × 10 6 cells per millilitre were infected with P1 virus at a multiplicity of infection of 5. Cells were harvested by centrifugation 48 h after infection and stored at − 80 °C until use. Purification of CCR2-T4L. Insect cell membranes were prepared by thawing frozen cell pellets in a hypotonic buffer containing 10 mM HEPES (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, and EDTA-free complete protease inhibitor cocktail tablets (Roche). Extensive washing of the raw membranes was performed by repeated douncing and centrifugation in the same hypotonic buffer (two or three times) and then in a high osmotic buffer containing 1.0 M NaCl, 10 mM HEPES (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, and EDTA-free complete protease inhibitor cocktail tablets (three or four times), thereby separating soluble and membrane associated proteins from integral transmembrane proteins. Stock solutions (40 mM) of BMS-681 and CCR2-RA-[R] were made in isopropanol. Washed membranes were resuspended into a buffer containing 50 μ M BMS-681, 2 mg/ml iodoacetamide, and EDTA-free complete protease inhibitor cocktail tablets, and incubated at 4 °C for 1 h before solubilization. The membranes were then solubilized in 50 mM HEPES (pH 7.5), 400 mM NaCl, 1% (w/v) n-dodecyl-β -d-maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma) at 4 °C for 3 h. The supernatant was isolated by centrifugation at 50,000g for 30 min, and incubated in 20 mM HEPES (pH 7.5), 400 mM NaCl with TALON IMAC resin (Clontech) overnight at 4 °C. After binding, the resin was washed without addition of ligands with ten column volumes of Wash I Buffer (50 mM HEPES (pH 7.5), 400 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10 mM imidazole), followed by four column volumes of Wash II Buffer (50 mM HEPES (pH 7.5), 400 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.01% (w/v) CHS, 50 mM imidazole). The protein was then eluted with three to four column volumes of Elution Buffer (50 mM HEPES (pH 7.5), 1 μ M BMS-681, 400 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.01% (w/v) CHS, 250 mM imidazole). PD MiniTrap G-25 columns (GE Healthcare) were used to remove imidazole. The protein was then treated overnight with His-tagged PreScission protease to cleave the C-terminal His-tag and Flag-tag. PreScission protease and the cleaved C-terminal fragment were removed by binding to TALON IMAC resin for 2 h at 4 °C. The protein was collected as the TALON IMAC column flow-through. The protein was supplemented with 75 μ M each of BMS-681 and CCR2-RA-[R] before being concentrated to 30 mg/ml with a 100 kDa molecular mass cut-off Amicon centrifuge concentrator (Millipore). The estimated final compound concentrations were ~1-2 mM for both compounds. Protein stability assays. The thermostability of CCR2-T4L was analysed by a differential scanning fluorimetry assay adapted from previous publications 33 using a RotorGene Q 6-plex RT-PCR machine (Qiagen). Briefly, 1-5 μ g of protein was mixed with 3 μ M 7-diethylamino-3-(4′ -maleimidylphenyl)-4-methylcoumarin (CPM) dye (2.5 mM stock in DMSO) in 25 mM HEPES pH 7.5, 400 mM NaCl, 0.02% DDM, 0.004% CHS, 10% glycerol, and indicated concentrations of compounds to a final volume of 20 μ l; samples were incubated for 5 min at room temperature and then heated gradually from 28 °C to 90 °C at a rate of 0.8 °C/ min, with CPM fluorescence (excitation 365 nm, emission 460 nm) recorded every 1 °C. The melting temperature (T m ) was determined from the first derivative of the denaturation curve, using Rotor-Gene Q -Pure Detection software (version 2.0.3). Crystallization. Purified CCR2 in complex with BMS-681 and CCR2-RA-[R] was reconstituted into LCP by mixing with molten lipid using a mechanical syringe mixer 8 . The protein-LCP mixture contained 40% (w/w) receptor solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystallization trials were performed in 96-well glass sandwich plates (Hampton research) using a Mosquito LCP robot (TTP Labtech) by dispensing 45 nl of protein-laden LCP and 800 nL of precipitant solution per well. Plates were incubated and imaged at 20 °C. Initial crystal hits were found from a precipitant condition containing 100 mM MES, pH 6.5, 30% (v/v) PEG400, 100 mM Li 2 SO 4 . After optimization, diffraction-quality crystals were obtained from 100 mM MES, pH 6.5, 30-32% (v/v) PEG400, 75-85 mM Li 2 SO 4 . Crystals usually grew to a maximum size of 60 μ m × 10 μ m × 10 μ m in 1 week, and were harvested directly from the LCP matrix using MiTeGen micromounts and flash cooled in liquid nitrogen. Data collection and structure determination. X-ray diffraction data were collected using a 10 μ m collimated minibeam at a wavelength of 1.0332 Å with a Pilatus3 6M direct detector on the 23ID-D beamline (GM/CA CAT) of the Advanced Photon Source at the Argonne National Laboratory. Crystals were located and aligned by the rastering strategy 34 . Among the several hundred crystal samples screened, most crystals diffracted to 2.8-3.5 Å resolution when exposed to 0.3 s of unattenuated beam using 0.3° oscillations. A 93.1% complete data set at 2.80 Å resolution was obtained by merging data from 17 crystals, using XDS 35 and Aimless 36 . As the data showed anisotropy, the UCLA Diffraction Anisotropy Server (http://services.mbi.ucla.edu/anisoscale/) was used to truncate the data to 3.0 Å along both a* and b* axes, and to 2.81 Å along the c* axis. Initial phase information was obtained by molecular replacement with the program Phaser 37 using the receptor portion of the CCR5 structure (PDB accession number 4MBS) converted to polyalanines, and the T4L portion of the CXCR4 structure (PDB accession number 3ODU) as search models. The correct molecular replacement solution (translation function Z-score = 14.8) contained one CCR2-T4L molecule in the asymmetric unit. Refinement was performed with Phenix 38 followed by manual examination and rebuilding of the refined coordinates in the program COOT 39 using both | 2F o | − | F c | and | F o | − | F c | maps, as well as omit maps. The final model included 295 residues (37-225 and 241-319) of the 360 residues of CCR2 and residues 2-161 of T4L plus 16 residues of two 8-residue linkers. The remaining N-and C-terminal residues were disordered and were not built. Strong electron density for one metal ion was observed. The identity of the ion was determined to be Zn 2+ by X-ray fluorescence scans (Extended Data Fig. 5 ). The zinc ion is coordinated by a water molecule as well as side chains of H144 3.56 , E238, and E1005. Data collection and refinement statistics are shown in Extended Data Table 1 . Crystallization and structure determination of BMS-681. BMS-681 was dissolved in a minimal amount of CH 3 CN and then 15% water was added. After standing overnight, the resulting crystals were collected. Data were obtained on a Bruker-AXS X8-Proteum Kappa goniometer and APEXII detector. Intensities were measured using Cu Kα radiation (λ = 1.5418 Å) with the crystal kept at a constant temperature using an Oxford cryo system during data collection. Indexing and processing of the measured intensity data were performed with the SAINT-APEX2 (Bruker-AXS) program suite, structure solution with SHELXS-97, and structure refinement with SHELXL-97.
The derived atomic parameters (coordinates and temperature factors) were refined through full matrix least-squares. The function minimized in the refinements was
where w is an appropriate weighting function based on errors in the observed intensities. Hydrogens were introduced in idealized positions with isotropic temperature factors, but no hydrogen parameters were varied. It should be noted that the refinement model illustrates disorder and partial occupancy factors of 'guest' solvent/water molecules within the crystalline lattice. The atomic positions of these disordered molecules were taken from the difference map analysis, which showed peaks of electron density of varying intensities at the refined positions representing the disordered solvent/water molecules. Data collection and refinement statistics are shown in Extended Data Table 2 . Cell culture and transfections. Chinese hamster ovary (CHO) cells (provided by H. den Dulk, Leiden University, The Netherlands; originally obtained from and certified by American Type Culture Collection) were cultured in Dulbecco's Modified Eagle Medium/F-12 Nutrient Mixture (DMEM/F-12) supplemented with 10% (v/v) newborn calf serum, 50 IU/ml penicillin, and 50 μ g/ml streptomycin; they were maintained at 37 °C and in 5% CO 2. Cells were subcultured twice a week at a ratio of 1:30 to 1:50 by trypsinization. Transient transfection of CHO cells with WT CCR2 and CCR2-T4L constructs was performed using a polyethylenimine method, as described previously 23 . Briefly, CHO cells were grown on plates (diameter 15 cm) to around 50% confluence and then transfected with a DNA/ polyethylenimine mixture containing 10 μ g plasmid DNA-previously diluted in 150 mM NaCl solution-mixed with polyethylenimine solution (1 mg/ml) at a 1:6 DNA:polyethylenimine mass ratio. Before adding 1 ml of the transfection mixture to each plate, the culture medium of the cells was refreshed and the mixture incubated for 20 min at room temperature. Following transfection, cells were incubated for 48 h at 37 °C and 5% CO 2 before membrane preparation.
Twenty-four hours after transfection, sodium butyrate was added to each plate at a final concentration of 3 mM to increase receptor expression. CHO cells were tested for mycoplasma contamination before use, the outcome of which was negative. Membrane preparation. Membranes from CHO cells transiently expressing the WT CCR2 or CCR2-T4L were prepared as described previously 23 . Briefly, cells were detached from plates (diameter 15 cm) using 5 ml of phosphate-buffered saline and centrifuged for 5 min at 3000g. The membranes were separated from the cytosolic fractions by several centrifugation and homogenization steps. First, the pellets were resuspended and homogenized in ice-cold membrane buffer (50 mM Tris-HCl buffer, supplemented with 5 mM MgCl 2 , pH 7.4) using an Ultra Thurrax Homogenizer (IKA-Werke, Staufen, Germany). Homogenized membranes were then centrifuged in an Optima LE-80 K ultracentrifuge (Beckman Coulter, Fullerton, California, USA) at 31,000g for 20 min at 4 °C. The final membrane pellet was resuspended also in ice-cold membrane buffer and aliquoted before storage. Membrane aliquots were stored at − 80 °C and protein concentrations were measured using a standard BCA protein determination assay (Pierce Chemical Company, Rockford, Illinois, USA). Radioligand binding assays. [ 3 H]INCB-3344 (specific activity 32 Ci mmol −1 ) and [ 3 H]CCR2-RA (specific activity 63 Ci mmol −1 ) were custom-labelled by Vitrax (Placentia, California, USA). JNJ-27141491 was synthesized as described previously 40 . INCB-3344 and CCR2-RA-[R] were synthesized in-house as described previously 7, 41 .
All radioligand binding assays were performed at 25 °C in a 100 μ L reaction volume containing assay buffer (50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl 2 , 0.1% CHAPS) and 30 μ g of membrane protein from CHO cells transiently expressing WT CCR2 or CCR2-T4L. For competition binding assays with [ 3 H] INCB-3344, a concentration of 5 nM [ 3 H]INCB-3344 was used, and non-specific binding was determined with 10 μ M of unlabelled INCB-3344. In the case of [ 3 H] CCR2-RA competition binding assays, a radioligand concentration of 3 nM was used and non-specific binding was determined with 10 μ M of JNJ-27141491. In all cases, homologous or competition displacement assays were performed using six increasing concentrations of competing ligands. Kinetic experiments were also performed at 25 °C using 7 nM [ 3 H]CCR2-RA and 30 μ g of membrane protein in a 100 μ l reaction volume. For association experiments, CHO-CCR2 or CHO-CCR2-T4L membranes were added to the reaction at eight different time points, in the absence or presence of 1 μ M BMS-681. For dissociation experiments, membranes were first incubated with radioligand for 90 min; dissociation was then initiated by addition of 10 μ M of CCR2-RA-[R] at 12 different time points, in the presence or absence of 1 μ M BMS-681. More time points were used in the dissociation assays, to characterize the biphasic profile of [ 3 H]CCR2-RA dissociation. In all cases, total radioligand binding did not exceed 10% of the total radioligand added to avoid ligand depletion. For all experiments, incubation was terminated by dilution with ice-cold wash buffer (50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl 2 , 0.05% CHAPS). Separation of bound from free radioligand was achieved by rapid filtration over a 96-well GF/B filter plate using a Perkin Elmer Filtermate-harvester (Perkin Elmer, Groningen, The Netherlands) and filter-bound radioactivity was determined in a Perkin Elmer 2450 Microbeta2 plate counter after addition of 25 μ l Microscint scintillation cocktail per well (Perkin-Elmer, Groningen, The Netherlands). Statistical methods. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
All radioligand binding data were analysed using Prism 6.0 and 7.0 (GraphPad Software, San Diego, California, USA). The pIC 50 values were obtained by nonlinear regression analysis of competition displacement assays. Apparent association rate constants (k obs ) and maximum binding (B max , used to calculate %B/B control ) were determined by fitting the association data to a one-phase exponential association function. Dissociation rate constants were determined by fitting the dissociation data to a monophasic (k off ) or biphasic (k off, fast and k off, slow ) exponential decay model. All data shown represent means ± s.e.m. of at least three independent experiments performed in duplicate. An unpaired, two-tailed Student's t-test was used to compare differences in pIC 50 as well as differences in kinetic parameters. Differences in binding enhancement (%Binding) in the absence (set at 100%) or presence of BMS-681 were analysed using a oneway analysis of variance with Dunnett's post-hoc test. Significant differences are denoted as follows: * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. Extended Data Figure 5 | A Zn 2+ binding site was identified by X-ray fluorescence emission analysis of the CCR2-T4L-BMS-681-CCR2-RA-[R] crystals. a, View of the Zn 2+ ion at an interface formed by CCR2 helices III and VI and the N terminus of T4L. The Zn 2+ ion is coordinated by side chains of H144 3.56 (from WT receptor), E238 6.30 (from the engineered part of the receptor), and E1005 (from T4L) as well as a structured water. b, Background fluorescence signal of an empty MiTeGen micromount is low, indicating the absence of metal ion. Excitation at 12 keV results in a peak at 11.7 keV (owing to the incidence beam). c, X-ray fluorescence emission signal from a wide fluorescence scan of the CCR2-T4L crystal. The fluorescence peaks at 8.60 keV and 9.53 keV correspond to X-ray emission lines K α (8.64 keV) and K β (9.57 keV) and indicate the presence of Zn 2+ bound to CCR2-T4L. d, A zoomed-in view of the X-ray fluorescence emission signal from c.
